How much does one year of treatment with ivonib cost? What are some ways to reduce the financial burden?

Ivosidenib is currently on the market in China, but since it has not been included in medical insurance, the cost of treatment for patients is relatively expensive. Usually, the cost of treatment for a year can be as high as 30,000 to 40,000 yuan. This cost is calculated for adult patients using standard doses. Since ivonib is mainly used to treat blood system cancers such as acute myeloid leukemia (AML), and the treatment cycle is usually long, the cost of long-term treatment may put greater financial pressure on patients.

In response to this high cost of treatment, patients can choose different ways to reduce their financial burden. First, some hospitals may offer installment payment or financial support plans through which patients can spread the cost of treatment, thereby easing the financial pressure of a single payment. Some hospitals may also help patients apply for charitable funds or other assistance programs, which sometimes provide subsidies or exemptions for some drug costs.

In addition, patients can also reduce treatment costs by purchasing drugs overseas. At present, generic drugs of Avonib are sold in some overseas markets, such as Laos. The price of generic ivonib drugs produced in Laos is about more than 3,000 yuan, which is far lower than the price of domestic original drugs. The ingredients of generic drugs are similar to the original drugs and have passed corresponding quality certification, so they have become a choice for many patients to reduce the burden of treatment. However, when purchasing overseas drugs, patients need to ensure that the source of the drugs is formal and avoid purchasing counterfeit and substandard drugs.
Finally, for patients undergoing long-term treatment, the government and relevant institutions should also promote the coverage of medical insurance, especially anti-cancer drugs for some specific diseases, and promote the expansion of medical insurance coverage. With the gradual improvement of policies, it is possible that ivonib will be included in medical insurance in the future, thus reducing the cost of treatment for patients. In short, patients can effectively reduce the financial burden caused by treatment costs by rationally choosing payment methods, generic drug channels, and paying attention to policy changes.
Reference link: https://www.tibsovo.com/